Overview

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Eligibility

Inclusion Criteria:

• Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
  • Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy

OR

• Subjects who have or have had a solid tumor diagnosis and any of the following:
  • At least 4 months of exposure to a PARP inhibitor
  • Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm

Exclusion Criteria:

• Individuals with a life expectancy of less than 6 months